Lates News

Swiss pharmaceutical company Ypsomed Holding AG plans to transfer some of its production capacity to Germany and increase production in the United States in order to reduce the impact of the 39% tariff threat from US President Trump on Switzerland. The company is accelerating its investment on the East Coast of the US, with the new plan to start production in the second half of 2027, a year earlier than originally planned.